Throughout the projected period, the worldwide chronic kidney disease medicines market is predicted to rise due to an increase in medication approvals by regulatory authorities and ongoing research & development of innovative treatments for chronic kidney disease. Grupo Olmos, a supplier of renal care solutions, announced in July 2022 that it had purchased the renal care business of Diaverum, an Argentine renal healthcare provider. The purchase of the renal business will help the company's renal product portfolio. The worldwide chronic renal disease pharmaceuticals market is projected to be hampered by a lack of knowledge of the condition. An early identification of chronic kidney disease (CKD) might delay disease development, avoid complications, and improve cardiovascular outcomes. It has also been proven that early referral to a nephrologist improves outcomes for people who advance to end-stage renal disease.
According to Coherent Market Insights, Global Chronic Kidney Disease Drugs Market is estimated to be valued at US$ 13, 220.0 million in 2022 and is expected to exhibit a CAGR of 4.5% during the forecast period (2022-2030).
Prominent Companies in the Chronic Kidney Disease Drugs Industry:
1. Sanofi
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. Sanofi was founded in 1973 and is headquartered in Paris, France.
2. AstraZeneca plc.
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. In June 2020, AstraZeneca announced its collaboration with Accent Therapeutics to discover, develop, and commercialize transformative therapeutics targeting RNA-modifying proteins for the treatment of cancer. In August 2021, AstraZeneca plc., announced that Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, had been approved in Japan for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D).
3. Amgen, Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California. In August 2020, Amgen Inc. received the U.S. Food and Drug Administration (FDA) approval for the expansion of Kyprolis (Carfilzomib) in combination with Darzalex plus Dexamethasone in two dosing regimens for the treatment of relapsed multiple myeloma. In January 2020, Amgen Inc. and BeiGene announced strategic collaboration to expand its oncology presence in China. Moreover, Amgen Inc. collaborated with Guardant Health Inc. And Qiagen to accelerate the molecular testing for patients with Non-small Cell Lung Cancer.
4. Bayer AG
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins and other consumer healthcare products. Founded in 1863, headquartered in Germany. On June 30, 2022, Bayer AG, announced that the Chinese National Medical Products Administration (NMPA) had granted marketing authorization for Finerenone under the brand name Kerendia. Kerendia (10 mg or 20 mg), a non-steroidal, selective mineralocorticoid receptor (MR) antagonist, is indicated for the treatment of chronic kidney disease (CKD).
5. F. Hoffmann-La Roche AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, and internationally. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD). Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.
6. GlaxoSmithKline plc.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV. Founded in 2000, headquartered in England, U.K.
7. Novartis AG
The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. In January 2020, Novartis AG announced that it had completed acquisition of The Medicines Company, a pharmaceutical company. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol.
8. Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company in Japan. The company markets its original products, such as the anti-prostatic cancer agent leuprolide acetate (marketed as Lupron Depot, Enantone, Prostap, and Leuplin), the anti-peptic ulcer agent lansoprazole (marketed as Prevacid, Ogast, Takepron, and other names), the anti-hypertensive agent candesartan cilexetil (marketed as Blopress, Kenzen, and Amias), and the anti-diabetic agent pioglitazone hydrochloride (marketed as Actos). Segments the company operates its business in two categories, Pharmaceutical business and Other businesses. The company was founded in 1781.
*Definition- Chronic kidney disease refers to disorders that cause kidney damage and reduce their capacity to keep you healthy by filtering wastes from your blood.
